Benchmark Initiates Coverage on 180 Life Sciences (NASDAQ:FRMM)

Key Points

• Benchmark initiated coverage with a "speculative buy" and a $5 price target (implying ~132.6% upside), while Weiss Ratings started coverage with a "sell (e+)", leaving the stock's consensus at an average "Hold" rating.
• The shares plunged about 21.8% to open at $2.15 (near its 12‑month low) after a year that saw a high of $174.60, highlighting extreme recent volatility.
• 180 Life Sciences is a clinical‑stage biotech focused on fibrosis, anti‑TNF, synthetic CBD analogs and a7nAChR platforms; it reported quarterly results showing a ($12.14) EPS loss on $2.44 million in revenue.

Research analysts at Benchmark began coverage on shares of 180 Life Sciences (NASDAQ:FRMM - Get Free Report) in a report released on Tuesday,Benzinga reports. The firm set a "speculative buy" rating and a $5.00 price target on the stock. Benchmark's price objective would indicate a potential upside of 132.56% from the stock's previous close.

Separately, Weiss Ratings initiated coverage on shares of 180 Life Sciences in a report on Thursday. They set a "sell (e+)" rating on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $5.00.

180 Life Sciences Trading Down 21.8%

NASDAQ:FRMM opened at $2.15 on Tuesday. The company has a current ratio of 10.07, a quick ratio of 10.07 and a debt-to-equity ratio of 1.11. 180 Life Sciences has a twelve month low of $2.15 and a twelve month high of $174.60.

180 Life Sciences (NASDAQ:FRMM - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($12.14) earnings per share for the quarter. The company had revenue of $2.44 million for the quarter.

About 180 Life Sciences

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.